Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 9/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6272841 | 0.88 | PPARD (0.43) | PPARDMKNK1MKNK2RCE1 | |
| SCHEMBL6539408 | 0.85 | CA12 (0.43) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL6228805 | 0.81 | MKNK1 (0.50) | CA1CA2PPARDMKNK1MKNK2 | |
| SCHEMBL6256472 | 0.80 | PPARD (0.41) | BCHECNR2PPARDMKNK1MKNK2 | |
| SCHEMBL6538954 | 0.79 | PPARD (0.38) | PPARDMKNK1MKNK2RCE1 | |
| SCHEMBL6539472 | 0.79 | HRH3 (0.38) | PPARDMKNK1MKNK2RCE1 | |
| SCHEMBL6207227 | 0.78 | PPARD (0.44) | PPARDMKNK1MKNK2RCE1 | |
| SCHEMBL6539668 | 0.78 | MTNR1A (0.58) | PPARD | |
| SCHEMBL6539344 | 0.77 | HPGD (0.42) | CA12CA2CA9PPARDRCE1 | |
| SCHEMBL6539675 | 0.77 | MEN1 (0.51) | PPARDMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | CA12 3116/4885CA1 1632/4885CA2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.